Literature DB >> 16924464

A model to infer the pathogenic significance of CDH1 germline missense variants.

Gianpaolo Suriano1, Susana Seixas, Jorge Rocha, Raquel Seruca.   

Abstract

Germline mutations of the E-cadherin gene (CDH1) are involved in the tumorigenesis of hereditary diffuse gastric cancer (HDGC). Recent studies have highlighted the lifesaving potential of total prophylactic gastrectomy for CDH1 germline mutation carriers. In this regard, CDH1 germline mutations of the missense type represent a clinical burden in genetic counseling, as their pathogenic relevance is not straightforward. In this work, we have outlined a possible multivariate approach to infer the significance of such variants. We reviewed all HDGC-associated E-cadherin germline missense mutations reported to date. The information collected included: co-segregation of the mutation within pedigrees, frequency in healthy population control, recurrence in independent families, and functional in vitro and in silico data. We used the neighbor-joining method to group mutations according to the collected information and assessed the robustness of mutation clusters with a bootstrap test. CDH1 germline missense variants were classified according to the parameters defined in the multivariate analysis. This analysis allowed the distribution of the variants into two distinct groups: neutral variants vs mutations. The model described in this study provides an important tool that can ultimately improve the genetic counseling offered to the carriers of the germline CDH1 missense variants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924464     DOI: 10.1007/s00109-006-0091-z

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  30 in total

Review 1.  Familial gastric cancer: overview and guidelines for management.

Authors:  C Caldas; F Carneiro; H T Lynch; J Yokota; G L Wiesner; S M Powell; F R Lewis; D G Huntsman; P D Pharoah; J A Jankowski; P MacLeod; H Vogelsang; G Keller; K G Park; F M Richards; E R Maher; S A Gayther; C Oliveira; N Grehan; D Wight; R Seruca; F Roviello; B A Ponder; C E Jackson
Journal:  J Med Genet       Date:  1999-12       Impact factor: 6.318

2.  The neighbor-joining method: a new method for reconstructing phylogenetic trees.

Authors:  N Saitou; M Nei
Journal:  Mol Biol Evol       Date:  1987-07       Impact factor: 16.240

Review 3.  Genetics, pathology, and clinics of familial gastric cancer.

Authors:  Carla Oliveira; Raquel Seruca; Fátima Carneiro
Journal:  Int J Surg Pathol       Date:  2006-01       Impact factor: 1.271

4.  E-cadherin germline mutations in familial gastric cancer.

Authors:  P Guilford; J Hopkins; J Harraway; M McLeod; N McLeod; P Harawira; H Taite; R Scoular; A Miller; A E Reeve
Journal:  Nature       Date:  1998-03-26       Impact factor: 49.962

5.  Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred.

Authors:  Carla Oliveira; Maria Cristina Bordin; Nicola Grehan; David Huntsman; Gianpaolo Suriano; José Carlos Machado; Tuula Kiviluoto; Lauri Aaltonen; Charles E Jackson; Raquel Seruca; Carlos Caldas
Journal:  Hum Mutat       Date:  2002-05       Impact factor: 4.878

6.  Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers.

Authors:  Beatrix Vécsey-Semjén; Karl-Friedrich Becker; Alexandra Sinski; Elizabeth Blennow; Ilja Vietor; Kurt Zatloukal; Hartmut Beug; Ernst Wagner; Lukas A Huber
Journal:  Oncogene       Date:  2002-07-11       Impact factor: 9.867

7.  The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell-cell adhesion and to suppress invasion.

Authors:  Gianpaolo Suriano; David Mulholland; Olivier de Wever; Paulo Ferreira; Ana Rita Mateus; Eric Bruyneel; Colleen C Nelson; Marc M Mareel; Jun Yokota; David Huntsman; Raquel Seruca
Journal:  Oncogene       Date:  2003-08-28       Impact factor: 9.867

8.  Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients.

Authors:  G Keller; H Vogelsang; I Becker; S Plaschke; K Ott; G Suriano; A R Mateus; R Seruca; K Biedermann; D Huntsman; C Döring; E Holinski-Feder; A Neutzling; J R Siewert; H Höfler
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

Review 9.  Mutations of the human E-cadherin (CDH1) gene.

Authors:  G Berx; K F Becker; H Höfler; F van Roy
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

10.  E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer.

Authors:  Tomonori Yabuta; Kazuya Shinmura; Masachika Tani; Satoru Yamaguchi; Kimio Yoshimura; Hitoshi Katai; Takashi Nakajima; Erito Mochiki; Toshimasa Tsujinaka; Motohisa Takami; Kazuo Hirose; Akio Yamaguchi; Seiichi Takenoshita; Jun Yokota
Journal:  Int J Cancer       Date:  2002-10-10       Impact factor: 7.396

View more
  21 in total

Review 1.  A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary diffuse gastric cancer.

Authors:  Rajini Seevaratnam; Natalie Coburn; Roberta Cardoso; Matthew Dixon; Alina Bocicariu; Lucy Helyer
Journal:  Gastric Cancer       Date:  2011-12-10       Impact factor: 7.370

2.  Familial gastric cancer: update for practice management.

Authors:  Giovanni Corso; Daniele Marrelli; Franco Roviello
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

Review 3.  Recognition of and recent issues in hereditary diffuse gastric cancer.

Authors:  Shinya Sugimoto; Hirokazu Komatsu; Yuichi Morohoshi; Takanori Kanai
Journal:  J Gastroenterol       Date:  2015-06-07       Impact factor: 7.527

Review 4.  Hereditary gastric cancer.

Authors:  F Carneiro
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

5.  Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants.

Authors:  Kristy Lee; Kate Krempely; Maegan E Roberts; Michael J Anderson; Fatima Carneiro; Elizabeth Chao; Katherine Dixon; Joana Figueiredo; Rajarshi Ghosh; David Huntsman; Pardeep Kaurah; Chimene Kesserwan; Tyler Landrith; Shuwei Li; Arjen R Mensenkamp; Carla Oliveira; Carolina Pardo; Tina Pesaran; Matthew Richardson; Thomas P Slavin; Amanda B Spurdle; Mackenzie Trapp; Leora Witkowski; Charles S Yi; Liying Zhang; Sharon E Plon; Kasmintan A Schrader; Rachid Karam
Journal:  Hum Mutat       Date:  2018-11       Impact factor: 4.878

6.  The identification and management of hereditary diffuse gastric cancer in a large Jordanian family.

Authors:  Henry T Lynch; Ibrahim Aldoss; Jane F Lynch
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

7.  A novel CDH1 germline missense mutation in a sporadic gastric cancer patient in north-east of Italy.

Authors:  Marica Garziera; Valli De Re; Silvano Geremia; Raquel Seruca; Joana Figueiredo; Soraia Melo; Joana Simões-Correia; Laura Caggiari; Mariangela De Zorzi; Vincenzo Canzonieri; Renato Cannizzaro; Giuseppe Toffoli
Journal:  Clin Exp Med       Date:  2012-04-29       Impact factor: 3.984

Review 8.  Hereditary diffuse gastric cancer: What the clinician should know.

Authors:  Ryan Ying Cong Tan; Joanne Ngeow
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

9.  Rare missense neuronal cadherin gene (CDH2) variants in specific obsessive-compulsive disorder and Tourette disorder phenotypes.

Authors:  Pablo R Moya; Nicholas H Dodman; Kiara R Timpano; Liza M Rubenstein; Zaker Rana; Ruby L Fried; Louis F Reichardt; Gary A Heiman; Jay A Tischfield; Robert A King; Marzena Galdzicka; Edward I Ginns; Jens R Wendland
Journal:  Eur J Hum Genet       Date:  2013-01-16       Impact factor: 4.246

10.  The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC.

Authors:  Joana Figueiredo; Ola Söderberg; Joana Simões-Correia; Karin Grannas; Gianpaolo Suriano; Raquel Seruca
Journal:  Eur J Hum Genet       Date:  2012-08-01       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.